Skip to main content

Table 4 Changes in GSRS scores by FLV and FLV+TJ-43 treatment.

From: Rikkunshi-to attenuates adverse gastrointestinal symptoms induced by fluvoxamine

GSRS score

pre-treatment

post-treatment

 

Total

   

   FLV

2.42 ± 1.24

2.52 ± 0.99

n.s.

   FLV+TJ-43

2.45 ± 1.10

1.97 ± 0.81

*

Reflux

   

   FLV

2.13 ± 1.46

2.50 ± 1.35

n.s.

   FLV+TJ-43

2.37 ± 1.61

2.00 ± 0.91

n.s.

Abdominal pain

   

   FLV

2.63 ± 1.56

3.18 ± 1.81

n.s.

   FLV+TJ-43

3.03 ± 1.82

2.18 ± 1.00

+

Indigestion

   

   FLV

1.70 ± 0.97

1.87 ± 0.74

n.s.

   FLV+TJ-43

2.05 ± 0.95

1.78 ± 1.06

n.s.

Diarrhea

   

   FLV

2.87 ± 1.78

2.35 ± 1.60

n.s.

   FLV+TJ-43

2.25 ± 1.47

1.65 ± 1.06

+

Constipation

   

   FLV

2.64 ± 1.87

2.83 ± 1.33

n.s.

   FLV+TJ-43

2.66 ± 1.69

2.34 ± 1.53

n.s.

  1. FLV = fluvoxamine; TJ-43 = Rikkunshito. mean ± SD. * p < 0.05, + p < 0.1 by paired t-test.
Back to article page

BioPsychoSocial Medicine

ISSN: 1751-0759

Contact us